

Congenital Adrenal Hyperplasia

2026 IFCAH project grant support

Key Dates:

January 15, 2026: Letters of intention (LOI) due date

February 2026: LOI decision meeting

April 2026: Full application due date (for accepted LOIs)

June 2026: Audition of proposals

July 2026: Award notification

Background

IFCAH is a private fund, aimed to promote research on Congenital Adrenal Hyperplasia (CAH). In 2024, it launches its call for proposals, in association with ESPE and ESE. A total amount of **350.000 €** is associated to this program. **Participation is open worldwide** and will, if possible, include teams based in Europe.

Specific goals

Proposition of new therapeutic targets and protocols

Pharmacotherapy, development of gene or/and cellular therapy models, improvement of current treatment monitoring.

Increasing knowledge on pathophysiology of CAH

The projects should be relevant to CAH. The projects could include research on adrenal development, differentiation and homeostasis, but in any case, relevance to CAH should be emphasized. Research on adrenal tumours and cancer is excluded from this call.

Prevention, diagnostic and treatment of natural or iatrogenic complications

Impact on foetal development, growth, puberty, effects on metabolic and cardiovascular systems, male and female fertility, bone density, immunity, infection, neuro cognition.

Funding

Selected research projects will be supported **up to EUR 150k (total)**. Funding period will have to start at the latest 6 months after notification of the award and will not exceed three years. Funds will have to be used for expenses directly linked to the project, including specific equipment, operating costs or salaries of co-workers (with the exception of salaries of senior permanent staff of academic and governmental agencies which are not eligible). Indirect costs or managements fees are not eligible and must be covered by another source. The funding is open to **co-funding opportunities** in order to support larger projects.

Eligibility

Applicants must hold an M.D., Ph.D., or equivalent academic degree and have a faculty position or equivalent at a college, university, medical school, or comparable institution. Only one project from a research team will be considered. Applications for the renewal of an IFCAH's support are accepted but applications for a different project, from a team previously supported by IFCAH, will not be considered, up to the end of its former grant.

Selection procedures

The information given on LOI will enable the scientific board of IFCAH, ESPE and ESE to access the priority of the projects and to determine whether the proposed research merits a full application. Applicants will have to inform on project positioning versus international competitors. Full applications will be requested from selected LOIs and submitted to peer-review. Final selection will take place after an oral project's presentation (on site in Paris or through video-conference) to the IFCAH, ESPE and ESE board.

An e-mail confirming that we received your application will be addressed to you. Please contact us if you do not receive this confirmation.

Additional information is available on www.ifcah.com or by sending a mail to cfp@ifcah.org.

Specific forms for letters of intent can be obtained from cfp@ifcah.org